首页> 外文OA文献 >LB0001 EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PsA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

【2h】

LB0001 EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PsA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

机译：LB0001 uPAdacitinib的疗效和安全性与安慰剂和Adalimalab有活跃的银屑病关节炎，对非生物疾病改性抗风湿药物的反应不足（选择-PSA-1）：双盲随机控制第3阶段试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
I. Mcinnes; J. Anderson; M. Magrey; J. F. Merola; Y. Liu; M. Kishimoto; S. Jeka; C. F. Pacheco Tena; X. Wang; L. Chen; P. Zueger; A. Pangan; F. Behrens;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Burmester Gerd R., Kremer Joel M., Van den Bosch Filip, The Lancet . 2018,第10139期

机译：upadacitinib在类风湿性关节炎患者中的安全性和疗效和对常规合成疾病改性抗风湿药物的反应不足（选择 - 下一步）：随机，双盲，安慰剂控制第3期试验
2. A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease-modifying antirheumatic drugs with active psoriatic arthritis [J] . Mease P. J., van der Heijde D., Ritchlin C. T., Experimental dermatology . 2017,第3期

机译：随机，双盲，活性和安慰剂对照第3期，Ixekizumab，Adalimalab和安慰剂治疗的疗效和安全性与活跃的银屑病关节炎的生物疾病改性抗逆肿瘤药物Naivence
3. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial [J] . Genovese Mark C., Fleischmann Roy, Combe Bernard, The Lancet . 2018,第10139期

机译：upadacitinib在活性类风湿性关节炎患者对生物疾病改性抗风湿药物难治的安全性和有效性（选择 - 超越）：双盲，随机对照第3阶段试验
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials [O] . Zhi-Peng Wu, Pei Zhang, Jian-Zhong Bai, -1

机译：对传统的合成或可改变生物疾病的抗风湿药反应不足的患者Baricitinib治疗活动性类风湿关节炎的疗效和安全性：一项随机对照试验的荟萃分析
7. OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL [O] . M. C. Genovese, A. Lertratanakul, J. Anderson, 2020

机译：OP0223 upadacitinib在有活跃的银屑病关节炎患者中的疗效和安全性和对生物疾病改性抗风湿药物的反应不足（SELECT-PSA-2）：双盲，随机对照第3阶段试验

LB0001 EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PsA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

著录项

引文网络

相似文献

相关主题

期刊订阅